Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result
The aim of this study was to retrospectively describe the genetic testing motives and experiences of women with a previous breast and/or ovarian cancer diagnosis, who received negative BRCA1/2 results including variants of unknown significance and no pathogenic variant detected. One hundred and thir...
Gespeichert in:
Veröffentlicht in: | Journal of community genetics 2019-10, Vol.10 (4), p.501-514 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 514 |
---|---|
container_issue | 4 |
container_start_page | 501 |
container_title | Journal of community genetics |
container_volume | 10 |
creator | Stafford, Lesley Flehr, Alison Judd, Fiona Lindeman, Geoffrey J. Gibson, Penny Komiti, Angela Mann, G. Bruce Kentwell, Maira |
description | The aim of this study was to retrospectively describe the genetic testing motives and experiences of women with a previous breast and/or ovarian cancer diagnosis, who received negative
BRCA1/2
results including variants of unknown significance and no pathogenic variant detected. One hundred and thirteen women (mean age 56.17 years) were recruited from a familial cancer centre in metropolitan Australia, an average 3.4 years after undergoing testing. Participants completed a self-report questionnaire focusing on the retrospective experience of and motives for undergoing
BRCA1/2
testing. The study found that the primary motives for undergoing
BRCA1/2
testing were (a) to know more about whether their cancer was hereditary, and (b) to have more certainty about the risk of their children developing cancer. In terms of perceptions of personal risk, 35% of women perceived that their risk of breast cancer to be the same or lower than the general population and 80% believed the negative test result to mean that a risk-conferring gene had not been detected. Yet, the average estimate of the likelihood that their cancer was hereditary was 48 out of a possible 100. Psychologically, women did not interpret the negative
BRCA1/2
result as a positive outcome. Half were not relieved by the result and were as or more worried than before. Psychological morbidity was high with 17%, 100%, and 36% experiencing clinically significant depression, anxiety, and cancer-specific distress, respectively. Self-ratings of the likelihood that their cancer was hereditary were more closely associated with their personal family cancer histories than with measures of psychological distress. These results have implications for adherence to risk-reducing behaviours and quality of life. Given that these women are not routinely followed up in clinical practice, these findings highlight the importance of post-test genetic counselling and longer-term follow-up for women with negative
BRCA1/2
results. Additional time and emotional support from genetic counsellors may help this group of women make sense of the meaning of their test result and adjust psychologically, particularly to uncertainty around the cause of their family history. |
doi_str_mv | 10.1007/s12687-019-00415-w |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6754479</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2294511341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-9be0031f6bd6a2874215b5c45fb1e14d7496f66de5528ae34e903a9cce7ff7b33</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEolXpH-CALHHhEuqJPxJfkMqqQKVKSAgkbpbjjLepEnuxnd32yi_HsNvyccAHe-R55vWM36p6DvQ1UNqeJWhk19YUVE0pB1HvHlXH0MmulpTC40PMgH49qk5TuqFlMQZCiqfVEaMKFGv4cfX94naDcURvMRHjBzL6jHETMZs8Bp9IcOTtp9U5nDUkY8qjXxMzh7LvwoyeGOfQZhxIf0f6iCZlEiIJWxNH44k1RTeS3XUgES2O2wIa4nFdxLdY7tIy5WfVE2emhKeH86T68u7i8-pDffXx_eXq_Kq2vOW5Vj2WCcDJfpCm6VregOiF5cL1gMCHlivppBxQiKYzyDgqyoyyFlvn2p6xk-rNXnez9DMOFn2OZtKbOM4m3ulgRv13xo_Xeh22WraC81YVgVcHgRi-LeUz9Dwmi9NkPIYl6QaUgtKYFAV9-Q96E5boy3i6aRQXAIxDoZo9ZWNIKaJ7aAao_umy3rusi8v6l8t6V4pe_DnGQ8m9pwVgeyCVlF9j_P32f2R_AJUrtT8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2294511341</pqid></control><display><type>article</type><title>Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result</title><source>Springer Nature - Complete Springer Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Stafford, Lesley ; Flehr, Alison ; Judd, Fiona ; Lindeman, Geoffrey J. ; Gibson, Penny ; Komiti, Angela ; Mann, G. Bruce ; Kentwell, Maira</creator><creatorcontrib>Stafford, Lesley ; Flehr, Alison ; Judd, Fiona ; Lindeman, Geoffrey J. ; Gibson, Penny ; Komiti, Angela ; Mann, G. Bruce ; Kentwell, Maira</creatorcontrib><description>The aim of this study was to retrospectively describe the genetic testing motives and experiences of women with a previous breast and/or ovarian cancer diagnosis, who received negative
BRCA1/2
results including variants of unknown significance and no pathogenic variant detected. One hundred and thirteen women (mean age 56.17 years) were recruited from a familial cancer centre in metropolitan Australia, an average 3.4 years after undergoing testing. Participants completed a self-report questionnaire focusing on the retrospective experience of and motives for undergoing
BRCA1/2
testing. The study found that the primary motives for undergoing
BRCA1/2
testing were (a) to know more about whether their cancer was hereditary, and (b) to have more certainty about the risk of their children developing cancer. In terms of perceptions of personal risk, 35% of women perceived that their risk of breast cancer to be the same or lower than the general population and 80% believed the negative test result to mean that a risk-conferring gene had not been detected. Yet, the average estimate of the likelihood that their cancer was hereditary was 48 out of a possible 100. Psychologically, women did not interpret the negative
BRCA1/2
result as a positive outcome. Half were not relieved by the result and were as or more worried than before. Psychological morbidity was high with 17%, 100%, and 36% experiencing clinically significant depression, anxiety, and cancer-specific distress, respectively. Self-ratings of the likelihood that their cancer was hereditary were more closely associated with their personal family cancer histories than with measures of psychological distress. These results have implications for adherence to risk-reducing behaviours and quality of life. Given that these women are not routinely followed up in clinical practice, these findings highlight the importance of post-test genetic counselling and longer-term follow-up for women with negative
BRCA1/2
results. Additional time and emotional support from genetic counsellors may help this group of women make sense of the meaning of their test result and adjust psychologically, particularly to uncertainty around the cause of their family history.</description><identifier>ISSN: 1868-310X</identifier><identifier>EISSN: 1868-6001</identifier><identifier>DOI: 10.1007/s12687-019-00415-w</identifier><identifier>PMID: 30919324</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Anxiety ; Biomedical and Life Sciences ; Biomedicine ; BRCA1 protein ; Breast cancer ; Epidemiology ; Gene Function ; Gene Therapy ; Genetic counseling ; Genetic screening ; Human Genetics ; Morbidity ; Original ; Original Article ; Ovarian cancer ; Public Health ; Quality of life ; Womens health</subject><ispartof>Journal of community genetics, 2019-10, Vol.10 (4), p.501-514</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2019</rights><rights>Copyright Springer Nature B.V. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-9be0031f6bd6a2874215b5c45fb1e14d7496f66de5528ae34e903a9cce7ff7b33</citedby><cites>FETCH-LOGICAL-c474t-9be0031f6bd6a2874215b5c45fb1e14d7496f66de5528ae34e903a9cce7ff7b33</cites><orcidid>0000-0002-6460-9881</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754479/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754479/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51298,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30919324$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stafford, Lesley</creatorcontrib><creatorcontrib>Flehr, Alison</creatorcontrib><creatorcontrib>Judd, Fiona</creatorcontrib><creatorcontrib>Lindeman, Geoffrey J.</creatorcontrib><creatorcontrib>Gibson, Penny</creatorcontrib><creatorcontrib>Komiti, Angela</creatorcontrib><creatorcontrib>Mann, G. Bruce</creatorcontrib><creatorcontrib>Kentwell, Maira</creatorcontrib><title>Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result</title><title>Journal of community genetics</title><addtitle>J Community Genet</addtitle><addtitle>J Community Genet</addtitle><description>The aim of this study was to retrospectively describe the genetic testing motives and experiences of women with a previous breast and/or ovarian cancer diagnosis, who received negative
BRCA1/2
results including variants of unknown significance and no pathogenic variant detected. One hundred and thirteen women (mean age 56.17 years) were recruited from a familial cancer centre in metropolitan Australia, an average 3.4 years after undergoing testing. Participants completed a self-report questionnaire focusing on the retrospective experience of and motives for undergoing
BRCA1/2
testing. The study found that the primary motives for undergoing
BRCA1/2
testing were (a) to know more about whether their cancer was hereditary, and (b) to have more certainty about the risk of their children developing cancer. In terms of perceptions of personal risk, 35% of women perceived that their risk of breast cancer to be the same or lower than the general population and 80% believed the negative test result to mean that a risk-conferring gene had not been detected. Yet, the average estimate of the likelihood that their cancer was hereditary was 48 out of a possible 100. Psychologically, women did not interpret the negative
BRCA1/2
result as a positive outcome. Half were not relieved by the result and were as or more worried than before. Psychological morbidity was high with 17%, 100%, and 36% experiencing clinically significant depression, anxiety, and cancer-specific distress, respectively. Self-ratings of the likelihood that their cancer was hereditary were more closely associated with their personal family cancer histories than with measures of psychological distress. These results have implications for adherence to risk-reducing behaviours and quality of life. Given that these women are not routinely followed up in clinical practice, these findings highlight the importance of post-test genetic counselling and longer-term follow-up for women with negative
BRCA1/2
results. Additional time and emotional support from genetic counsellors may help this group of women make sense of the meaning of their test result and adjust psychologically, particularly to uncertainty around the cause of their family history.</description><subject>Anxiety</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>BRCA1 protein</subject><subject>Breast cancer</subject><subject>Epidemiology</subject><subject>Gene Function</subject><subject>Gene Therapy</subject><subject>Genetic counseling</subject><subject>Genetic screening</subject><subject>Human Genetics</subject><subject>Morbidity</subject><subject>Original</subject><subject>Original Article</subject><subject>Ovarian cancer</subject><subject>Public Health</subject><subject>Quality of life</subject><subject>Womens health</subject><issn>1868-310X</issn><issn>1868-6001</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQhiMEolXpH-CALHHhEuqJPxJfkMqqQKVKSAgkbpbjjLepEnuxnd32yi_HsNvyccAHe-R55vWM36p6DvQ1UNqeJWhk19YUVE0pB1HvHlXH0MmulpTC40PMgH49qk5TuqFlMQZCiqfVEaMKFGv4cfX94naDcURvMRHjBzL6jHETMZs8Bp9IcOTtp9U5nDUkY8qjXxMzh7LvwoyeGOfQZhxIf0f6iCZlEiIJWxNH44k1RTeS3XUgES2O2wIa4nFdxLdY7tIy5WfVE2emhKeH86T68u7i8-pDffXx_eXq_Kq2vOW5Vj2WCcDJfpCm6VregOiF5cL1gMCHlivppBxQiKYzyDgqyoyyFlvn2p6xk-rNXnez9DMOFn2OZtKbOM4m3ulgRv13xo_Xeh22WraC81YVgVcHgRi-LeUz9Dwmi9NkPIYl6QaUgtKYFAV9-Q96E5boy3i6aRQXAIxDoZo9ZWNIKaJ7aAao_umy3rusi8v6l8t6V4pe_DnGQ8m9pwVgeyCVlF9j_P32f2R_AJUrtT8</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Stafford, Lesley</creator><creator>Flehr, Alison</creator><creator>Judd, Fiona</creator><creator>Lindeman, Geoffrey J.</creator><creator>Gibson, Penny</creator><creator>Komiti, Angela</creator><creator>Mann, G. Bruce</creator><creator>Kentwell, Maira</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6460-9881</orcidid></search><sort><creationdate>20191001</creationdate><title>Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result</title><author>Stafford, Lesley ; Flehr, Alison ; Judd, Fiona ; Lindeman, Geoffrey J. ; Gibson, Penny ; Komiti, Angela ; Mann, G. Bruce ; Kentwell, Maira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-9be0031f6bd6a2874215b5c45fb1e14d7496f66de5528ae34e903a9cce7ff7b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anxiety</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>BRCA1 protein</topic><topic>Breast cancer</topic><topic>Epidemiology</topic><topic>Gene Function</topic><topic>Gene Therapy</topic><topic>Genetic counseling</topic><topic>Genetic screening</topic><topic>Human Genetics</topic><topic>Morbidity</topic><topic>Original</topic><topic>Original Article</topic><topic>Ovarian cancer</topic><topic>Public Health</topic><topic>Quality of life</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stafford, Lesley</creatorcontrib><creatorcontrib>Flehr, Alison</creatorcontrib><creatorcontrib>Judd, Fiona</creatorcontrib><creatorcontrib>Lindeman, Geoffrey J.</creatorcontrib><creatorcontrib>Gibson, Penny</creatorcontrib><creatorcontrib>Komiti, Angela</creatorcontrib><creatorcontrib>Mann, G. Bruce</creatorcontrib><creatorcontrib>Kentwell, Maira</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of community genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stafford, Lesley</au><au>Flehr, Alison</au><au>Judd, Fiona</au><au>Lindeman, Geoffrey J.</au><au>Gibson, Penny</au><au>Komiti, Angela</au><au>Mann, G. Bruce</au><au>Kentwell, Maira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result</atitle><jtitle>Journal of community genetics</jtitle><stitle>J Community Genet</stitle><addtitle>J Community Genet</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>10</volume><issue>4</issue><spage>501</spage><epage>514</epage><pages>501-514</pages><issn>1868-310X</issn><eissn>1868-6001</eissn><abstract>The aim of this study was to retrospectively describe the genetic testing motives and experiences of women with a previous breast and/or ovarian cancer diagnosis, who received negative
BRCA1/2
results including variants of unknown significance and no pathogenic variant detected. One hundred and thirteen women (mean age 56.17 years) were recruited from a familial cancer centre in metropolitan Australia, an average 3.4 years after undergoing testing. Participants completed a self-report questionnaire focusing on the retrospective experience of and motives for undergoing
BRCA1/2
testing. The study found that the primary motives for undergoing
BRCA1/2
testing were (a) to know more about whether their cancer was hereditary, and (b) to have more certainty about the risk of their children developing cancer. In terms of perceptions of personal risk, 35% of women perceived that their risk of breast cancer to be the same or lower than the general population and 80% believed the negative test result to mean that a risk-conferring gene had not been detected. Yet, the average estimate of the likelihood that their cancer was hereditary was 48 out of a possible 100. Psychologically, women did not interpret the negative
BRCA1/2
result as a positive outcome. Half were not relieved by the result and were as or more worried than before. Psychological morbidity was high with 17%, 100%, and 36% experiencing clinically significant depression, anxiety, and cancer-specific distress, respectively. Self-ratings of the likelihood that their cancer was hereditary were more closely associated with their personal family cancer histories than with measures of psychological distress. These results have implications for adherence to risk-reducing behaviours and quality of life. Given that these women are not routinely followed up in clinical practice, these findings highlight the importance of post-test genetic counselling and longer-term follow-up for women with negative
BRCA1/2
results. Additional time and emotional support from genetic counsellors may help this group of women make sense of the meaning of their test result and adjust psychologically, particularly to uncertainty around the cause of their family history.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30919324</pmid><doi>10.1007/s12687-019-00415-w</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-6460-9881</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1868-310X |
ispartof | Journal of community genetics, 2019-10, Vol.10 (4), p.501-514 |
issn | 1868-310X 1868-6001 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6754479 |
source | Springer Nature - Complete Springer Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Anxiety Biomedical and Life Sciences Biomedicine BRCA1 protein Breast cancer Epidemiology Gene Function Gene Therapy Genetic counseling Genetic screening Human Genetics Morbidity Original Original Article Ovarian cancer Public Health Quality of life Womens health |
title | Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T14%3A48%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Experiences%20and%20interpretations%20of%20BRCA1/2%20testing%20among%20women%20affected%20by%20breast%20or%20ovarian%20cancer%20who%20received%20a%20negative%20result&rft.jtitle=Journal%20of%20community%20genetics&rft.au=Stafford,%20Lesley&rft.date=2019-10-01&rft.volume=10&rft.issue=4&rft.spage=501&rft.epage=514&rft.pages=501-514&rft.issn=1868-310X&rft.eissn=1868-6001&rft_id=info:doi/10.1007/s12687-019-00415-w&rft_dat=%3Cproquest_pubme%3E2294511341%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2294511341&rft_id=info:pmid/30919324&rfr_iscdi=true |